Cidofovir Macure for CMV retinitis in AIDS patients
Quick answer: Cidofovir Macure is used for CMV retinitis in AIDS patients as part of a antiviral (nucleotide analogue) treatment regimen. Acyclic nucleoside phosphonate that inhibits viral DNA polymerase after intracellular phosphorylation The specific dosing for CMV retinitis in AIDS patients is determined by your prescriber based on individual factors.
Why is Cidofovir Macure used for CMV retinitis in AIDS patients?
Cidofovir Macure belongs to the Antiviral (nucleotide analogue) class. Acyclic nucleoside phosphonate that inhibits viral DNA polymerase after intracellular phosphorylation This action makes it useful for treating or managing CMV retinitis in AIDS patients in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Cidofovir Macure is the right choice for a specific patient depends on the type and severity of CMV retinitis in AIDS patients, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for CMV retinitis in AIDS patients
Common adult dosing range: 5 mg/kg IV once weekly for 2 weeks, then every 2 weeks (with probenecid and hydration). The actual dose for CMV retinitis in AIDS patients depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Cidofovir Macure medicine page.
What to expect
Cidofovir Macure treatment for CMV retinitis in AIDS patients typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on CMV retinitis in AIDS patients
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Cidofovir Macure is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Antiviral (nucleotide analogue) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Cidofovir Macure
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Cidofovir Macure full prescribing information · All Antiviral (nucleotide analogue) alternatives
Frequently asked questions
How effective is Cidofovir Macure for CMV retinitis in AIDS patients?
Effectiveness varies by individual response, dose, and severity. Cidofovir Macure is one of several treatment options for CMV retinitis in AIDS patients, supported by clinical evidence within the antiviral (nucleotide analogue) class. Discuss expected response with your prescriber.
How long do I need to take Cidofovir Macure for CMV retinitis in AIDS patients?
Treatment duration depends on the nature of CMV retinitis in AIDS patients — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Cidofovir Macure when used for CMV retinitis in AIDS patients?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Cidofovir Macure for CMV retinitis in AIDS patients?
Yes. Multiple medicines and non-drug options exist for CMV retinitis in AIDS patients. Alternatives within the antiviral (nucleotide analogue) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.